Article
Ultradeep sequencing study of chronic hepatitis C virus genotype 1 infection in patients treated with daclatasvir, peginterferon, and ribavirin.
Antimicrobial agents and chemotherapy - 1 Jan 2014
Murakami Eisuke, Imamura Michio, Hayes C Nelson, Abe Hiromi, Hiraga Nobuhiko, Honda Yoji, Ono Atsushi, Kosaka Keiichi, Kawaoka Tomokazu, Tsuge Masataka, Aikata Hiroshi, Takahashi Shoichi, Miki Daiki, Ochi Hidenori, Matsui Hirotaka, Kanai Akinori, Inaba Toshiya, McPhee Fiona, Chayama Kazuaki
Abstract excerpt
Direct-acting antivirals (DAAs) are either part of the current standard of care or are in advanced clinical development for the treatment of patients chronically infected with hepatitis C virus (HCV) genotype 1, but concern exists with respect to the patients who fail these regimens with emergent drug-resistant variants. In the present study, ultradeep sequencing was performed to analyze resistance to daclatasvir...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.